Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eisai Plots A Meticulous Path To CMS Coverage For Lecanemab

US Exec Ivan Cheung Expects ‘More Open Access’ To Drug

Executive Summary

The company believes the Phase III Clarity AD results offer a high level of evidence that may convince the Centers for Medicare and Medicaid Services to change its stance on anti-amyloid antibodies for lecanemab. 

You may also be interested in...

Lilly Does Not Expect A Quick Medicare Coverage Decision For Donanemab

Donanemab may receive accelerated approval for Alzheimer’s disease in early 2023, but Lilly will not approach CMS about Medicare coverage until mid-year when it has Phase III data – and even then does not expect a quick decision. 

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: US prospects for Sarepta’s DMD gene therapy; looking at price increases in the US; Eisai plans US CMS coverage for lecanemab; vaccine impact as China rolls back COVID zero policies; and ex-Novo Nordisk CEO Mads Øvlisen shares his career and life lessons.

Clearing Amyloid Provides Alzheimer’s Benefit, But With Risks That Need Careful Management

Eisai/Biogen’s lecanemab showed that reducing amyloid can slow Alzheimer’s disease progression, but prescribers will have to weigh the potential benefit versus safety risks on a patient-by-patient basis.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts